Foghorn Therapeutics Inc. Stock-Based Compensation
Foghorn Therapeutics Inc. (FHTX) reported Stock-Based Compensation of $2.55 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- Foghorn Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $2.55M, a 6.70% decline year-over-year.
- Foghorn Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $2.38M, a 11.48% decline year-over-year.
- Foghorn Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $2.24M, a 9.75% decline year-over-year.
- Foghorn Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $2.73M, a 9.44% decline year-over-year.
- Foghorn Therapeutics Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $10.40M, a 12.56% decline from fiscal 2024.
- Foghorn Therapeutics Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $11.89M, a 26.52% decline from fiscal 2023.
- Foghorn Therapeutics Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $16.19M, a 12.90% increase from fiscal 2022.
- Foghorn Therapeutics Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $14.34M, a 70.99% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 3 month as first filed | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 9 month as first filed | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2.55M 10-Q · filed 2026-08-06 | $4.93M 10-Q · filed 2026-08-06 | $7.17M derived: sum of 3 quarters · filed 2026-08-06 | $9.91M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $2.38M 10-Q · filed 2026-05-07 | $4.62M derived: sum of 2 quarters · filed 2026-05-07 | $7.36M derived: sum of 3 quarters · filed 2026-05-07 | $10.09M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | $2.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $4.97M derived: sum of 2 quarters · filed 2026-03-11 | $7.71M derived: sum of 3 quarters · filed 2026-08-06 | $10.40M 10-K · filed 2026-03-11 | ||
| 2025-09-30 | $2.73M 10-Q · filed 2025-11-05 | $5.47M derived: sum of 2 quarters · filed 2026-08-06 | $8.16M 10-Q · filed 2025-11-05 | $10.64M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $2.73M 10-Q · filed 2026-08-06 | $5.42M 10-Q · filed 2026-08-06 | $7.91M derived: sum of 3 quarters · filed 2026-08-06 | $10.93M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $2.69M 10-Q · filed 2026-05-07 | $5.17M derived: sum of 2 quarters · filed 2026-05-07 | $8.19M derived: sum of 3 quarters · filed 2026-05-07 | $11.36M derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $2.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $5.50M derived: sum of 2 quarters · filed 2026-03-11 | $8.67M derived: sum of 3 quarters · filed 2026-03-11 | $11.89M 10-K · filed 2026-03-11 | ||
| 2024-09-30 | $3.02M 10-Q · filed 2025-11-05 | $6.19M derived: sum of 2 quarters · filed 2025-11-05 | $9.41M 10-Q · filed 2025-11-05 | $12.46M derived: sum of 4 quarters · filed 2025-11-05 | ||
| 2024-06-30 | $3.17M 10-Q · filed 2025-08-05 | $6.39M 10-Q · filed 2025-08-05 | $9.44M derived: sum of 3 quarters · filed 2025-08-05 | $13.54M derived: sum of 4 quarters · filed 2025-08-05 | ||
| 2024-03-31 | $3.22M 10-Q · filed 2025-05-14 | $6.28M derived: sum of 2 quarters · filed 2025-05-14 | $10.37M derived: sum of 3 quarters · filed 2025-05-14 | $14.84M derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | $3.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $7.14M derived: sum of 2 quarters · filed 2025-03-06 | $11.62M derived: sum of 3 quarters · filed 2025-03-06 | $16.19M 10-K · filed 2025-03-06 | ||
| 2023-09-30 | $4.09M 10-Q · filed 2024-11-04 | $8.56M derived: sum of 2 quarters · filed 2024-11-04 | $13.13M 10-Q · filed 2024-11-04 | $16.92M derived: sum of 4 quarters · filed 2024-11-04 | ||
| 2023-06-30 | $4.47M 10-Q · filed 2024-08-08 | $9.04M 10-Q · filed 2024-08-08 | $12.82M derived: sum of 3 quarters · filed 2024-08-08 | $16.63M derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2023-03-31 | $4.57M 10-Q · filed 2024-05-06 | $8.35M derived: sum of 2 quarters · filed 2024-05-06 | $12.15M derived: sum of 3 quarters · filed 2024-05-06 | $15.66M derived: sum of 4 quarters · filed 2024-05-06 | ||
| 2022-12-31 | $3.78M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $7.58M derived: sum of 2 quarters · filed 2024-03-07 | $11.09M derived: sum of 3 quarters · filed 2024-03-07 | $14.34M 10-K · filed 2024-03-07 | ||
| 2022-09-30 | $3.80M 10-Q · filed 2023-11-02 | $7.31M derived: sum of 2 quarters · filed 2023-11-02 | $10.55M 10-Q · filed 2023-11-02 | $12.64M derived: sum of 4 quarters · filed 2023-11-02 | ||
| 2022-06-30 | $3.51M 10-Q · filed 2023-08-04 | $6.75M 10-Q · filed 2023-08-04 | $8.84M derived: sum of 3 quarters · filed 2023-08-04 | $11.21M derived: sum of 4 quarters · filed 2023-08-04 | ||
| 2022-03-31 | $3.24M 10-Q · filed 2023-05-08 | $5.33M derived: sum of 2 quarters · filed 2023-05-08 | $7.70M derived: sum of 3 quarters · filed 2023-05-08 | $9.74M derived: sum of 4 quarters · filed 2023-05-08 | ||
| 2021-12-31 | $2.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $4.45M derived: sum of 2 quarters · filed 2023-03-09 | $6.50M derived: sum of 3 quarters · filed 2023-03-09 | $8.38M 10-K · filed 2023-03-09 | ||
| 2021-09-30 | $2.37M 10-Q · filed 2022-11-08 | $2.37M 10-Q · filed 2021-11-09 | $4.41M derived: sum of 2 quarters · filed 2022-11-08 | $6.30M 10-Q · filed 2022-11-08 | $6.30M 10-Q · filed 2021-11-09 | $7.38M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $2.04M 10-Q · filed 2022-08-09 | $3.93M 10-Q · filed 2022-08-09 | $5.01M derived: sum of 3 quarters · filed 2022-08-09 | $5.88M derived: sum of 4 quarters · filed 2022-08-09 | ||
| 2021-03-31 | $1.89M 10-Q · filed 2022-05-09 | $2.97M derived: sum of 2 quarters · filed 2022-08-09 | $3.84M derived: sum of 3 quarters · filed 2022-08-09 | $4.33M derived: sum of 4 quarters · filed 2022-08-09 | ||
| 2020-12-31 | $1.08M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-08-09 | $1.96M derived: sum of 2 quarters · filed 2022-08-09 | $2.44M derived: sum of 3 quarters · filed 2022-08-09 | $2.96M 10-K/A · filed 2022-08-09 | ||
| 2020-09-30 | $877.00K 10-Q · filed 2021-11-09 | $1.37M derived: sum of 2 quarters · filed 2021-11-09 | $1.88M 10-Q · filed 2021-11-09 | $2.45M derived: sum of 4 quarters · filed 2021-11-09 | ||
| 2020-06-30 | $489.00K 10-Q · filed 2021-08-10 | $1.01M 10-Q · filed 2021-08-10 | $1.58M derived: sum of 3 quarters · filed 2021-08-10 | $2.02M derived: sum of 4 quarters · filed 2021-08-10 | ||
| 2020-03-31 | $517.00K 10-Q · filed 2021-05-11 | $1.09M derived: sum of 2 quarters · filed 2021-05-11 | $1.53M derived: sum of 3 quarters · filed 2021-05-11 | |||
| 2019-12-31 | $570.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $1.01M derived: sum of 2 quarters · filed 2021-03-18 | $1.69M 10-K · filed 2021-03-18 | |||
| 2019-09-30 | $443.00K 10-Q · filed 2020-12-04 | $1.12M 10-Q · filed 2020-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |